Sichuan Kelun-Biotech Biopharmaceutical company profile
Company profile
Sichuan Kelun-Biotech Biopharmaceutical has 2,300 employees and is headquartered in Chengdu, China.
With 2,300 employees, Sichuan Kelun-Biotech develops, manufactures and sells novel medicines for oncology, immunology and metabolic conditions, serving patients in China and in overseas markets. Its pipeline rests largely on antibody-drug conjugates, among them Sac-TMT, a TROP2-directed candidate that can be used alone or alongside other treatments for advanced solid tumors, and trastuzumab botidotin for HER2-positive tumors. Further candidates include a CLDN18.2 conjugate, a Nectin-4 conjugate, the PD-L1 antibody tagitanlimab and the RET inhibitor A400. Licensing and collaboration agreements link the company to Merck Sharp & Dohme, Harbour BioMed, Windward Bio and Ellipses Pharma.
In the fiscal year ended December 2025, revenue reached 2.1 billion yuan, up 6.5% from the previous year, while the company recorded a net loss of 382.0 million yuan. The headquarters are in Chengdu. The company was incorporated in 2016 and is a subsidiary of Sichuan Kelun Pharmaceutical.
Company facts
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Hong Kong SAR China
- Headquarters
- No. 666 Xinhua Avenue, Chengdu
- Employees
- 2,300
- Chief executive
- Junyou Ge
- Founded
- 2016
- Fiscal year
- January - December
- Listing
- 6990 · HKEX
- Currency
- HKD
- ISIN
- CNE1000062J1
- Website
- kelun-biotech.com
Sichuan Kelun-Biotech Biopharmaceutical and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| Sichuan Kelun-Biotech Biopharmaceutical6990 | Hong Kong SAR China | $12.15B | 2,300 | -0.2% | — |
| Sino Biopharmaceutical1177 | Hong Kong SAR China | $11.65B | 22,838 | 28.2% | 34.2 |
| Pharmaron Beijing300759 | China | $10.59B | 25,088 | 14.0% | 39.3 |
| Innovent Biologics1801 | Hong Kong SAR China | $17.82B | 8,754 | 7.4% | 105.4 |
| ALTEOGEN196170 | South Korea | $9.05B | 181 | 47.2% | 97.1 |
| Haisco Pharmaceutical Group002653 | China | $8.97B | 5,597 | 21.1% | 44.1 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
Compare Sichuan Kelun-Biotech Biopharmaceutical with its competitors
